AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28569520 — intervention group
Group type: COMPARATOR
Intervention: Motivational Interviewing (MI)
Number of subjects: 44
Study 25908506 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss intervention + 2000 IU/day oral vitamin D3
Number of subjects: 218
Study 25908506 — intervention group
Group type: COMPARATOR
Intervention: Weight-loss intervention + daily placebo
Number of subjects: 218
Study 22682669 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib-first strategy
Number of subjects: 0
Study 22682669 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy-first strategy
Number of subjects: 0
Study 22436774 — intervention group
Group type: EXPERIMENTAL
Intervention: Talon (n = 28)
Number of subjects: 51
Study 22436774 — intervention group
Group type: COMPARATOR
Intervention: Wires only (control, n = 23)
Number of subjects: 51
Study 20048519 — intervention group
Group type: EXPERIMENTAL
Intervention: T-bow training program for lower limbs (8 weeks, 5 exercises: squat, lateral and frontal swings, lunges, plantarflexions)
Number of subjects: 28
Study 20048519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 16750455 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS XR 30 mg/d
Number of subjects: 308
Study 16750455 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS XR 40 mg/d
Number of subjects: 308
Study 16750455 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS XR
Number of subjects: 308
Study 16750455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 14729287 — intervention group
Group type: EXPERIMENTAL
Intervention: High monitors receiving extensive information
Number of subjects: 260
Study 14729287 — intervention group
Group type: EXPERIMENTAL
Intervention: Low monitors receiving minimal information
Number of subjects: 260
Study 14729287 — intervention group
Group type: COMPARATOR
Intervention: Standard care (usual information plus coaching by a nurse)
Number of subjects: 260
Study 11726729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated newborns without hypocapnia
Number of subjects: 777
Study 11726729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated newborns with hypocapnia
Number of subjects: 777
Study 11726729 — intervention group
Group type: COMPARATOR
Intervention: Unventilated newborns
Number of subjects: 777
Study 9416933 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release isosorbide mononitrate (ER-ISMN) 60 mg
Number of subjects: 151
Study 9416933 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release isosorbide mononitrate (ER-ISMN) 120 mg
Number of subjects: 151
Study 9416933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 8279667 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration (exact dosage not specified)
Number of subjects: 82
Study 8279667 — intervention group
Group type: COMPARATOR
Intervention: Control (no alcohol, exact dosage not specified)
Number of subjects: 82
Study 3300945 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptichemio (1.2 mg/kg/d) for two 5-day courses; Group 2
Number of subjects: 65
Study 3300945 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy to the tumor bed; Group 2 (children older than 1 year)
Number of subjects: 65
Study 3300945 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy; Group 2 (children older than 1 year)
Number of subjects: 65
Study 3300945 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete tumor resection; Group 1
Number of subjects: 65
Study 3300945 — intervention group
Group type: COMPARATOR
Intervention: No further antitumor therapy; Group 1
Number of subjects: 65
Study 28851121 — intervention group
Group type: EXPERIMENTAL
Intervention: External Facilitation (EF)
Number of subjects: 2
Study 28851121 — intervention group
Group type: COMPARATOR
Intervention: Educational Outreach Visits (EOV)
Number of subjects: 2
Study 28586623 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up survey measuring vaccine hesitancy scores
Number of subjects: 237
Study 28586623 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up survey measuring the proportion of vaccine hesitant mothers
Number of subjects: 237
Study 25534635 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization plus RF ablation
Number of subjects: 89
Study 25534635 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization plus MW ablation
Number of subjects: 89
Study 24024771 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard calorie‐ and fat‐restricted diet (STD‐D)
Number of subjects: 143
Study 24024771 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie‐ and fat‐restricted lacto‐ovo‐vegetarian diet (LOV‐D)
Number of subjects: 143
Study 24024771 — intervention group
Group type: COMPARATOR
Intervention: Weight loss
Number of subjects: 143
Study 19577829 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology (30-minute session for five consecutive days)
Number of subjects: 65
Study 19577829 — intervention group
Group type: COMPARATOR
Intervention: Control group (received the same care without reflexology therapy)
Number of subjects: 65
Study 17451581 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage plus cryosurgery (C&C)
Number of subjects: 100
Study 17451581 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision (SE)
Number of subjects: 100
Study 14984323 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (150 microg subcutaneously for two weeks)
Number of subjects: 0
Study 11794149 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily
Number of subjects: 1049
Study 11794149 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 30 mg twice daily
Number of subjects: 1049
Study 9677602 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute asthma
Number of subjects: 39
Study 9677602 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable asthma
Number of subjects: 39
Study 9677602 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute bronchiolitis
Number of subjects: 39
Study 9677602 — intervention group
Group type: COMPARATOR
Intervention: Controls (non-atopic)
Number of subjects: 39
Study 9677602 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV positive and RSV negative bronchiolitis
Number of subjects: 39
Study 9677602 — intervention group
Group type: EXPERIMENTAL
Intervention: sE‐selectin and sP‐selectin
Number of subjects: 39
Study 7988251 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate combination chemotherapy (CAP)
Number of subjects: 188
Study 7988251 — intervention group
Group type: COMPARATOR
Intervention: Delayed combination chemotherapy (CAP)
Number of subjects: 188
Study 2729939 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antacid (30 ml of aluminum hydroxide orally four times a day for 4 days)
Number of subjects: 6
Study 31386758 — intervention group
Group type: EXPERIMENTAL
Intervention: C8-silk lipoamino acid functionalized pigments (FA)
Number of subjects: 40
Study 31386758 — intervention group
Group type: COMPARATOR
Intervention: Pure pigments (FP)
Number of subjects: 40
Study 30442233 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet/Ca/D (cholecalciferol 50,000 IU/subject/week and calcium 1200 mg/dL/subject/day)
Number of subjects: 45
Study 30442233 — intervention group
Group type: COMPARATOR
Intervention: Diet/Ca (calcium 1200 mg/dL/subject/day)
Number of subjects: 45
Study 30442233 — intervention group
Group type: COMPARATOR
Intervention: CON (no prescribed supplements)
Number of subjects: 45
Study 25713312 — intervention group
Group type: EXPERIMENTAL
Intervention: Streaming video of antitobacco ads
Number of subjects: 1034
Study 25713312 — intervention group
Group type: COMPARATOR
Intervention: Screenshot of antitobacco ads
Number of subjects: 1034
Study 24648723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day, n=25)
Number of subjects: 50
Study 24648723 — intervention group
Group type: COMPARATOR
Intervention: No fluoxetine (control group, n=25)
Number of subjects: 50
Study 22198621 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea infusate (3 x 200 ml/day for 12 weeks)
Number of subjects: 100
Study 22198621 — intervention group
Group type: COMPARATOR
Intervention: Hot water (equivalent volume for same intervention period)
Number of subjects: 100
Study 20515467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rehydration (IVR)
Number of subjects: 750
Study 20515467 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric rehydration (NGR)
Number of subjects: 750
Study 18076246 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 22
Study 18076246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16146476 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 50 mg x 3
Number of subjects: 50
Study 16146476 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 12866828 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual discrimination tasks with increasing complexity
Number of subjects: 28
Study 12866828 — intervention group
Group type: COMPARATOR
Intervention: Auditory processing tasks (control)
Number of subjects: 28
Study 10393606 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone therapy
Number of subjects: 85
Study 10393606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 8930940 — intervention group
Group type: EXPERIMENTAL
Intervention: hGAL (80 pmol/kg/min for 60 minutes)
Number of subjects: 9
Study 8930940 — intervention group
Group type: COMPARATOR
Intervention: PD (120 mg orally)
Number of subjects: 9
Study 8930940 — intervention group
Group type: COMPARATOR
Intervention: PD and hGAL
Number of subjects: 9
Study 2034826 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution (15 ml/kg body weight) with lumbar epidural anesthesia
Number of subjects: 30
Study 2034826 — intervention group
Group type: COMPARATOR
Intervention: Control group (epidural anesthesia only, no hemodilution)
Number of subjects: 30
Study 2034826 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution
Number of subjects: 30
Study 6132819 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 8
Study 6132819 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 8
Study 30630342 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages encouraging influenza vaccination via e‐mails, texts, and postal mail
Number of subjects: 25649
Study 30630342 — intervention group
Group type: COMPARATOR
Intervention: Messages encouraging influenza vaccination via e‐mails and texts
Number of subjects: 25649
Study 30630342 — intervention group
Group type: COMPARATOR
Intervention: No messages
Number of subjects: 25649
Study 28715554 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosodic variation during ultrasound visual feedback training
Number of subjects: 6
Study 28715554 — intervention group
Group type: COMPARATOR
Intervention: No prosodic variation during ultrasound visual feedback training
Number of subjects: 6
Study 26525065 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive personalized method for cardiovascular prevention
Number of subjects: 12513
Study 26525065 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in global cardiovascular risk profile during the first year
Number of subjects: 12513
Study 24501384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG), once daily for 4 weeks
Number of subjects: 124
Study 24501384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 21963389 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (2×100 ml/d for 8 weeks)
Number of subjects: 30
Study 21963389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2×100 ml/d for 8 weeks)
Number of subjects: 30
Study 19362675 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg intravenous infusion)
Number of subjects: 833
Study 19362675 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (5 mg oral daily)
Number of subjects: 833
Study 17239114 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal cooling (ECO) using a cooled water-irrigated intraesophageal balloon (IB)
Number of subjects: 8
Study 17239114 — intervention group
Group type: COMPARATOR
Intervention: Control (no esophageal cooling)
Number of subjects: 8
Study 16339095 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg
Number of subjects: 364
Study 16339095 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg
Number of subjects: 364
Study 16339095 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg or 10 mg)
Number of subjects: 364
Study 16339095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 11960396 — intervention group
Group type: EXPERIMENTAL
Intervention: All trans retinoic acid (ATRA) 45 mg/m²/day from day 1 to complete remission combined with Idarubicin 10 mg/m²/day for 3 days and cytarabine 1000 mg/m²/12 h for 6 days.
Number of subjects: 95
Study 11960396 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin 10 mg/m²/day for 3 days and cytarabine 1000 mg/m²/12 h for 6 days without ATRA.
Number of subjects: 95
Study 11960396 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA combined with chemotherapy (Idarubicin and Cytarabine).
Number of subjects: 95
Study 10190855 — intervention group
Group type: EXPERIMENTAL
Intervention: CD pedicle screw implants
Number of subjects: 61
Study 10190855 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral fusions alone
Number of subjects: 61
Study 10190855 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoblast proliferation (excellent, good, poor)
Number of subjects: 61
Study 10190855 — intervention group
Group type: EXPERIMENTAL
Intervention: Age influence on osteoblast proliferation
Number of subjects: 61
Study 10190855 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative tobacco smoking
Number of subjects: 61
Study 7577781 — intervention group
Group type: COMPARATOR
Intervention: Blind standard technique (group A: 8 mL bupivacaine 0.25%)
Number of subjects: 12
Study 7577781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic imaging technique (group B: 5 mL bupivacaine 0.25%)
Number of subjects: 12
Study 2034479 — intervention group
Group type: EXPERIMENTAL
Intervention: HiFe (13.8 mg elemental iron)
Number of subjects: 55
Study 2034479 — intervention group
Group type: EXPERIMENTAL
Intervention: MidFe (7 mg elemental iron)
Number of subjects: 55
Study 2034479 — intervention group
Group type: COMPARATOR
Intervention: NatFe (no elemental iron)
Number of subjects: 55
Study 7326166 — intervention group
Group type: EXPERIMENTAL
Intervention: L(+) mepivacaine
Number of subjects: 23
Study 7326166 — intervention group
Group type: EXPERIMENTAL
Intervention: D(‐) mepivacaine
Number of subjects: 23
Study 7326166 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic mepivacaine
Number of subjects: 23
Study 7326166 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 23
Study 7326166 — intervention group
Group type: EXPERIMENTAL
Intervention: L(+) and D(‐) mepivacaine
Number of subjects: 23
Study 31907024 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 120
Study 31907024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 120
Study 31907024 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and cognitive training (ACT)
Number of subjects: 120
Study 30616692 — intervention group
Group type: EXPERIMENTAL
Intervention: CSNAT-Stroke intervention
Number of subjects: 0
Study 30616692 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 28837598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 117
Study 28837598 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 27266853 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable diuretic response and hemoconcentration in PROTECT trial
Number of subjects: 1180
Study 27266853 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable diuretic response and hemoconcentration in EVEREST trial
Number of subjects: 1180
Study 23557627 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg bid for 10 days)
Number of subjects: 64
Study 23557627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20499072 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie‐restricted legume‐based diet (L‐diet)
Number of subjects: 30
Study 20499072 — intervention group
Group type: COMPARATOR
Intervention: Calorie‐restricted legume-free diet (C‐diet)
Number of subjects: 30
Study 18282237 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide azithromycin treatment
Number of subjects: 1722
Study 16531164 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic OC containing 40/30 mug ethynylestradiol (EE)+25/125 mug desogestrel (DSG; n=10)
Number of subjects: 20
Study 16531164 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic OC containing 35 mug EE and 2 mg cyproterone acetate (CPA; n=10)
Number of subjects: 20
Study 12697594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.1 mg
Number of subjects: 6
Study 12697594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.2 mg
Number of subjects: 6
Study 12697594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 6
Study 12697594 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine 0.05 mg
Number of subjects: 6
Study 10895744 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine with fentanyl 1 microgram ml‐1
Number of subjects: 40
Study 10895744 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine with fentanyl 2 micrograms ml‐1
Number of subjects: 40
Study 10895744 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA ropivacaine with fentanyl
Number of subjects: 40
Study 10895744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration/high-volume solution
Number of subjects: 40
Study 9561637 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation for 12 weeks
Number of subjects: 144
Study 9561637 — intervention group
Group type: COMPARATOR
Intervention: Weekly iron supplementation for 12 weeks
Number of subjects: 144
Study 1532940 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary nebulized fenoterol (F) 1.25 mg and ipratropium (I) 0.5 mg for three weeks
Number of subjects: 20
Study 1532940 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 1532940 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual therapy
Number of subjects: 20
Study 3157576 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine (200 mg/day, increased to 300 mg/day after 7 days)
Number of subjects: 45
Study 3157576 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 45
Study 3157576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31779624 — intervention group
Group type: EXPERIMENTAL
Intervention: RESPOND intervention
Number of subjects: 263
Study 31779624 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 263
Study 28251784 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow-restricted exercise at 10% AOP
Number of subjects: 0
Study 28251784 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow-restricted exercise at 90% AOP
Number of subjects: 0
Study 28251784 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow-restricted exercise at various pressures
Number of subjects: 0
Study 28251784 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow-restricted exercise
Number of subjects: 0
Study 28251784 — intervention group
Group type: EXPERIMENTAL
Intervention: Common BFR protocol with 30% 1RM
Number of subjects: 0
Study 27746838 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith Repositioning Maneuver and Vestibular Rehabilitation for 13 weeks
Number of subjects: 14
Study 27746838 — intervention group
Group type: COMPARATOR
Intervention: Canalith Repositioning Maneuver
Number of subjects: 14
Study 27746838 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith Repositioning Maneuver and Vestibular Rehabilitation
Number of subjects: 14
Study 24590620 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture cleanser immersion for 3 min/day for seven consecutive days
Number of subjects: 2
Study 24590620 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 2
Study 22503790 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulation
Number of subjects: 0
Study 22503790 — intervention group
Group type: COMPARATOR
Intervention: Non-painful stimulation
Number of subjects: 0
Study 20470226 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific enteral formula
Number of subjects: 22
Study 18407382 — intervention group
Group type: EXPERIMENTAL
Intervention: AS‐H5N1 vaccine
Number of subjects: 5071
Study 18407382 — intervention group
Group type: COMPARATOR
Intervention: Fluarix (licensed seasonal influenza vaccine)
Number of subjects: 5071
Study 17569261 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Number of subjects: 250
Study 15206667 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine at >16 mg
Number of subjects: 0
Study 15206667 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone at 4 mg
Number of subjects: 0
Study 15206667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone at 120 mg
Number of subjects: 0
Study 15206667 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone at 2 mg daily
Number of subjects: 0
Study 15206667 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine at 6 mg
Number of subjects: 0
Study 15206667 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole at 10 mg daily
Number of subjects: 0
Study 15206667 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine above 400 mg
Number of subjects: 0
Study 15206667 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol at 3.3 to 10 mg
Number of subjects: 0
Study 15206667 — intervention group
Group type: COMPARATOR
Intervention: High doses of haloperidol
Number of subjects: 0
Study 15206667 — intervention group
Group type: COMPARATOR
Intervention: High doses of FGAs
Number of subjects: 0